ReviewCurrent opinion in HIV and AIDS2013
New paradigms for functional HIV-specific nonneutralizing antibodies.
Review in Current opinion in HIV and AIDS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.AIDS research and human retroviruses · 2017Trial
- Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Cell reports · 2026Article
- Comprehensive Mapping of the Virus and Host Factors that Guide the Paths of HIV-1 Escape from a Therapeutic.bioRxiv : the preprint server for biology · 2025Article
- So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.Viruses · 2022Review
- Article
- Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.Advanced drug delivery reviews · 2021Review
- A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.Journal of virology · 2020Article
- Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.Journal of virology · 2019Article
- Antibody responses to viral infections: a structural perspective across three different enveloped viruses.Nature microbiology · 2019Review
- Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus.Journal of virology · 2019Article
- Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.Frontiers in immunology · 2019Review
- An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.Frontiers in immunology · 2019Review
- Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.AIDS (London, England) · 2018Article
- Article
- Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.Journal of virology · 2018Article
- Progress in HIV vaccine development.Human vaccines & immunotherapeutics · 2017Review
- Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.Current HIV/AIDS reports · 2017Review
- Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines.Pathogens & immunity · 2017Article
- Survivors Remorse: antibody-mediated protection against HIV-1.Immunological reviews · 2017Review
- Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewAlthough a large number of novel broadly neutralizing antibodies has been recently described, the induction of such antibodies via vaccination has proven difficult. By contrast, nonneutralizing antibodies arise early during infection and have been repeatedly associated with both protection from infection and disease progression. RECENT
findingsWe are beginning to gain new insights into the broader landscape of antiviral mechanisms that nonneutralizing antibodies may harness to fight HIV, providing an unprecedented breadth of approaches by which HIV can be blocked and contained. SUMMARY: In this review, we summarize the characteristics of nonneutralizing antibodies, their role in HIV infection, and new paradigm-shifting functions that may be exploited by next-generation vaccine approaches aimed at blocking HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.